Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus
Lunai Bioworks issued $20 million in Series B preferred stock to acquire Neurobridge IP Holdings’ CNS drug-delivery and neurotherapeutic patents, closing the deal May 1. The company said the transaction lifts its stockholders’ equity above Nasdaq’s $2.5 million listing minimum. Lunai shares traded at $0.3246 Monday, leaving its market value at $7.6 million. The acquired assets consist solely of patents, with no cash paid.